
The senior vice president for Research and Training at Kessler Foundation talked about the issue of fatigue in patients with multiple sclerosis and the significant, multifaceted challenges patients face. [WATCH TIME: 5 minutes]
Senior Vice President for Research and Training, Kessler Foundation; Professor, Departments of Physical Medicine & Rehabilitation, and Neurology, Rutgers New Jersey Medical School

The senior vice president for Research and Training at Kessler Foundation talked about the issue of fatigue in patients with multiple sclerosis and the significant, multifaceted challenges patients face. [WATCH TIME: 5 minutes]

Cognitive problems have been reported to occur in as many as 7 in 10 individuals with MS, yet they remain a difficult and undertreated challenge in clinical care.

Dr DeLuca shares his advice and recommendations from National MS Society on providing cognitive care for patients suffering from MS.

Multiple sclerosis expert, Dr DeLuca, shares study design and clinical data on the association between brain volume and long-term cognition in patients with relapsing MS.

The senior vice president for research and training at the Kessler Foundation discussed the assessment of cognitive challenges among patients with multiple sclerosis and planning for treatment options when necessary. [WATCH TIME: 4 minutes]

The senior vice president for research and training at the Kessler Foundation spoke about the critical need to prioritize cognitive challenges among patients with multiple sclerosis, as it remains among the chief complaints. [WATCH TIME: 4 minutes]

Dr DeLuca provides an overview of changes in cognition and brain volume loss in patients with multiple sclerosis.

The Senior Vice President for Research and Training at Kessler Foundation spoke about research he and colleagues have developed at the Kessler Foundation to aid with cognitive problems in persons with MS.

The Senior Vice President for Research and Training at Kessler Foundation discussed the results of the SUNBEAM trial, which indicated that ozanimod resulted in sustained improvement in cognitive processing speed, supporting its efficacy in relapsing MS.

Published: July 4th 2022 | Updated:

Published: June 29th 2022 | Updated:

Published: July 6th 2022 | Updated:

Published: November 25th 2022 | Updated:

Published: March 30th 2019 | Updated:

Published: April 3rd 2019 | Updated: